Análisis Argos
TXG
TXGSin veredicto
10x Genomics, Inc. · Healthcare
US$ 39.01
precio al 2026-07-04
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
33/100
Sin veredicto
LA RESPUESTA
No tenemos un veredicto de valuación confiable acá: su flujo de caja no permite una estimación sólida. Mirá su calidad y su salud para formarte una idea — preferimos eso a inventarte un número.
Recompensas
Tiene más caja que deuda: balance fuerte.
Riesgos
!Balance frágil: la deuda pesa sobre el negocio.
VALOR1/6FUTURO5/6PASADO1/6SALUD1/6DIVIDENDO1/6
El Iris de calidad
VALOR1/6FUTURO5/6PASADO1/6SALUD1/6DIVIDENDO1/6
ValorCotiza por encima de su valor justo
FuturoIngresos creciendo con fuerza
PasadoHistorial débil
SaludBalance frágil
DividendoEl dividendo aún duerme
Score Argos33de 100Sin veredicto
Ingresos5%
US$ 0.6 B
Margen operativo46%
-17.2%
Flujo de caja libre1400%
US$ 0.1 B
Deuda neta
US$ -0.3 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 5.0B
P/E
EV/EBITDA
FCF yield2.6%
ROIC-23.1%
Margen operativo-17.2%
Crecim. ingresos+5.2%/año
Piotroski F4/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 19 jun
10x Genomics, Cleveland Clinic Team Up on Bladder Cancer Diagnostics
TXG collaborates with the Cleveland Clinic to advance bladder cancer diagnostics using Flex Apex, Xenium and potentially Atera.
newsfilecorp.com · 17 jun
Torex Gold Announces Results of Its 2026 Meeting of Shareholders
Meeting marks formal transition of Andrew Snowden into role of President and CEO Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) (OTCQX: TORXF) announces the results of its 2026 annual and special meeting of shareholders (the "Meeting") held virtually today. The Meeting marked the retirement of Jody Kuzenko and the formal appointment of Andrew Snowden as President and CEO of the Company.
seekingalpha.com · 17 jun
Torex Gold Resources Inc. (TXG:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Torex Gold Resources Inc. (TXG:CA) Shareholder/Analyst Call Prepared Remarks Transcript
prnewswire.com · 17 jun
10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer
Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms PLEASANTON, Calif., June 17, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance research in novel diagnostics for bladder cancer.
zacks.com · 10 jun
TXG Gains From Proteintech Deal, Expands Multiomics Capabilities
10x Genomics stock rises after acquiring Proteintech Genomics, adding high-plex proteomics tools that strengthen multiomics research and support platform adoption.
prnewswire.com · 9 jun
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
Acquisition Expands 10x Genomics' Capabilities in Proteomics PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the acquisition of Proteintech Genomics, a division within Proteintech Group, a company specializing in developing high-plex proteomic solutions for single cell and spatial applications on 10x platforms.
seekingalpha.com · 4 jun
10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript
10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript
fool.com · 1 jun
10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors.
10x Genomics, a leader in single cell and spatial genomics tools, reported a notable insider sale amid ongoing sector innovation.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.